A key finding was that 86% of patients required no additional therapy after receiving nadofaragene.
Gabriela M. Diáz, MD
Advertisement
Diáz is a research assistant at Cleveland Clinic in Cleveland, Ohio.
Articles by Gabriela M. Diáz, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves first-line Zenflow system for the treatment of BPH
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5
